Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Immune Design Corp. (IMDZ)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/20/2019 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Civitas, Entegra, and Immune Design on Behalf of Stockholders and Encourages Investors to Contact the Firm |
| 02/22/2019 |
GN
| Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Immune Design Corp. (IMDZ) on Behalf of Stockholders and Encourages IMDZ Investors to Contact the Firm |
| 02/21/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders |
| 12/04/2018 |
GN
| Detailed Research: Economic Perspectives on NanoString Technologies, Tyson Foods, Welbilt, Immune Design, Turning Point Brands, and LGI Homes — What Drives Growth in Today's Competitive Landscape |
| 12/02/2018 |
GN
| Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab |
| 11/20/2018 |
GN
| Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference |
| 11/06/2018 |
GN
| Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update |
| 11/06/2018 |
GN
| Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting |
| 10/25/2018 |
GN
| New Research Coverage Highlights Immune Design, QAD, Overseas Shipholding Group, Connecticut Water Service, Westport Fuel, and Monmouth Real Estate Investment — Consolidated Revenues, Company Growth, and Expectations for 2018 |
| 09/05/2018 |
GN
| Investor Expectations to Drive Momentum within CSW Industrials, On Deck Capital, Hurco Companies, PetMed Express, Sandstorm Gold, and Immune Design — Discovering Underlying Factors of Influence |
| 08/30/2018 |
GN
| Immune Design to Present at Upcoming September Investor Conferences |
| 07/25/2018 |
GN
| Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update |
| 05/02/2018 |
GN
| Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update |
| 03/07/2018 |
GN
| Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update |
| 02/09/2018 |
GN
| Immune Design to Present at Upcoming Investor Conferences |
| 01/30/2018 |
GN
| Consolidated Research: 2018 Summary Expectations for Immune Design, Primoris Services, Scotts Miracle-Gro, Heska, Calyxt, and Urstadt Biddle Properties — Fundamental Analysis, Key Performance Indications |
| 12/10/2017 |
GN
| Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients |
| 10/27/2017 |
GN
| Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update |
| 10/24/2017 |
GN
| Immune Design Prices $80.0 Million Public Offering of Common Stock |
| 10/23/2017 |
GN
| Immune Design Announces Proposed Public Offering of Common Stock |
| 10/16/2017 |
GN
| Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients |
| 09/25/2017 |
GN
| Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting |
| 09/08/2017 |
GN
| New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response |
| 09/01/2017 |
GN
| Immune Design to Present at Upcoming Investor Conferences in September |
| 08/30/2017 |
GN
| Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress |
| 06/05/2017 |
GN
| Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting |
| 06/01/2017 |
GN
| Immune Design to Present at Jefferies 2017 Global Healthcare Conference |
| 05/17/2017 |
GN
| New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms |
| 05/17/2017 |
GN
| Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update |
| 04/20/2017 |
GN
| Immune Design Announces Presentations at the 2017 ASCO Annual Meeting |
| 03/07/2017 |
GN
| Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update |
| 03/01/2017 |
GN
| Immune Design to Present New Tumor Eradication Data for Systemic Plus Intratumoral Immunization at the American Association for Cancer Research (AACR) Annual Meeting 2017 |
| 02/22/2017 |
GN
| Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate |
| 02/10/2017 |
GN
| Immune Design to Present at Upcoming Investor Conferences |
|
|